SeekingAlpha · Aug 28, 2026
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis. Read more on INMB stock here.
KR
NASDAQ · KRYS
Krystal Biotech, Inc.
Healthcare · Biotechnology
$359.36
Up+$7.90 (+2.25%)
Updated Sep 1, 2026, 4:18 AM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.16B
- P/E ratio
- 35.94
- Dividend yield
- 0.00%
- 52-week range
- $136.73 – $382.54
- Volume
- 222.78K
- Avg. volume
- 324.53K
Price performance
KRYS price history
1M range · 21 trading sessions · Daily adjusted prices
KRYS closed at $359.36 after 21 trading sessions, up 14.97% for the selected period.
- Last close
- $359.36
- Period change
- +14.97%
- Period low
- $312.57
- Period high
- $359.76
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $348.62 | $363.52 | $345.14 | $359.36 | 222.78K |
| Aug 28, 2026 | $356.92 | $356.92 | $348.57 | $351.46 | 143.51K |
| Aug 27, 2026 | $357.61 | $362.50 | $355.09 | $357.46 | 181.43K |
| Aug 26, 2026 | $354.37 | $363.82 | $350.43 | $359.76 | 281.03K |
| Aug 25, 2026 | $343.81 | $357.91 | $343.81 | $356.19 | 205.05K |
| Aug 24, 2026 | $343.51 | $346.5499 | $337.09 | $341.72 | 236.71K |
| Aug 21, 2026 | $337.44 | $348.03 | $335.72 | $346.58 | 407.81K |
| Aug 20, 2026 | $338.32 | $343.14 | $334.99 | $337.02 | 196.7K |
| Aug 19, 2026 | $339.61 | $345.5599 | $335.44 | $343.34 | 162.84K |
| Aug 18, 2026 | $332.18 | $337.405 | $330.31 | $332.82 | 148.47K |
| Aug 17, 2026 | $330.31 | $337.205 | $330.06 | $335.73 | 255.14K |
| Aug 14, 2026 | $333.85 | $333.85 | $320.62 | $332.27 | 167.86K |
| Aug 13, 2026 | $332.99 | $334.88 | $327.28 | $328.34 | 135.63K |
| Aug 12, 2026 | $326.95 | $334.21 | $325.00 | $332.86 | 161.95K |
| Aug 11, 2026 | $333.30 | $336.28 | $324.32 | $327.05 | 147.9K |
| Aug 10, 2026 | $324.54 | $332.73 | $324.54 | $331.59 | 151.95K |
| Aug 7, 2026 | $326.34 | $329.00 | $320.34 | $326.45 | 160.04K |
| Aug 6, 2026 | $323.46 | $329.52 | $320.94 | $322.69 | 206.29K |
| Aug 5, 2026 | $326.86 | $331.07 | $316.1544 | $325.78 | 324.61K |
| Aug 4, 2026 | $314.73 | $328.83 | $313.755 | $324.77 | 534.61K |
| Aug 3, 2026 | $320.70 | $332.305 | $297.02 | $312.57 | 1.17M |
Latest KRYS news
The latest Smart Investors Daily articles mentioning KRYS.
Stock researchCompany · Overview
KRYS research
Overview
Company profile and research snapshot.
Company profile
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $220.00
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
| Jul 14, 2026 | B of A Securities | Buy | — |
| Jun 18, 2026 | TD Cowen | Buy | — |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 25, 2026
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annualized basis producing an average annual return of 44.08%. Currently, Krystal Biotech has a market capitalization of
ChartMill · Aug 22, 2026
Krystal Biotech (NASDAQ:KRYS) Clears Minervini Trend Template and High Growth Momentum Screen
Krystal Biotech (KRYS) meets Minervini's Trend Template & High Growth Momentum screens: strong uptrend, high relative strength, and robust growth.
Yahoo · Aug 14, 2026
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says
Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
